| Autor: |
Marniquet, M.‐E., Joly, P., Dansette, D., Fenot, M. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Sep2022, Vol. 36 Issue 9, pe686-e688, 3p |
| Abstrakt: |
The patient in this manuscript has given written informed consent to publication of their case detail. The Pemphigus disease area index (PDAI) score in our patient was 76/250, which exceeds the severity threshold of 45 defining severe pemphigus.4,5 Based on recent recommendations for the management of moderate-to-severe pemphigus,4 adjuvant treatment with rituximab combined with systemic corticosteroid therapy was initiated. Factors Associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text